Long-term use of dual orexin receptor antagonists improves subjective sleep outcomes in adults with chronic insomnia
A systematic review and meta-analysis of 6 randomized controlled trials with 3,546 participants found that DORAs (suvorexant, lemborexant, daridorexant) improved subjective sleep parameters at 6 and 12 months. Adverse events were similar to placebo at 6 months but higher at 12 months, with no significant difference in overall discontinuation due to adverse events, though higher doses increased discontinuation at 6 months.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Long-term use of dual orexin receptor antagonists improves subjective sleep outcomes in adults with chronic insomnia The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 47/100 (low).
The Claim
Long-term use of dual orexin receptor antagonists improves subjective sleep outcomes in adults with chronic insomnia
This conclusion is most relevant to: Adults with chronic insomnia (primary insomnia).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Long-term use of dual orexin receptor antagonists for the treatment of insomnia: a systematic review and meta-analysis. (Arquivos de neuro-psiquiatria, 2026) —
How It Works
The proposed biological pathway:
- ▸DORAs block orexin receptors in the brain, reducing wakefulness signaling
- ▸This promotes sleep initiation and maintenance
- ▸Sustained blockade over months leads to continued improvement in sleep parameters
- ▸Result: Improved subjective sleep outcomes at 6 and 12 months with acceptable safety profile
Who Might Benefit
Evidence fit by population:
- ▸Adults with chronic insomnia (primary insomnia)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Only 6 RCTs included, limiting generalizability
- ▸Higher doses associated with increased discontinuation at 6 months, suggesting tolerability issues
- ▸Long-term safety beyond 12 months not assessed
Frequently Asked Questions
What are dual orexin receptor antagonists (DORAs)?▼
DORAs are medications that block orexin receptors in the brain, reducing wakefulness and helping treat insomnia. Examples include suvorexant, lemborexant, and daridorexant.
How long can DORAs be used for insomnia?▼
This meta-analysis supports use for at least 6 to 12 months, showing sustained improvements in sleep outcomes with acceptable safety, though higher doses may be less tolerated.
Are DORAs safe for long-term use?▼
Adverse events were similar to placebo at 6 months but higher at 12 months. Overall discontinuation due to adverse events was not significantly different, but higher doses increased discontinuation at 6 months.
Which DORAs were included in this study?▼
The study included FDA-approved DORAs: suvorexant, lemborexant, and daridorexant.
References
- 1.Araujo LMM, Sousa AD, Vieira CC, Abreu JPP, Conti CF, Silva MML, Oliveira MM. “Long-term use of dual orexin receptor antagonists for the treatment of insomnia: a systematic review and meta-analysis..” Arquivos de neuro-psiquiatria, 2026. PMID: 42595319 DOI: 10.1055/s-0046-1827049